<DOC>
	<DOCNO>NCT02080195</DOCNO>
	<brief_summary>The main goal study determine bone marrow transplant ( BMT ) less specific pool donor combination high dose cyclophosphamide induce remission refractory systemic lupus erythematosus .</brief_summary>
	<brief_title>Nonmyeloablative Conditioning Transplantation Patients With Refractory Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) devastate systemic autoimmune disease predominantly affect young woman , common African-Americans white , result poor quality life . Lupus cure , 90 % patient require corticosteroids disease control . More half patient lupus permanent organ damage , much either directly due increase corticosteroid . To satisfactorily manage moderate-to-severe SLE , need effective treatment allow corticosteroid-sparing . High-dose chemotherapy follow autologous BMT peripheral blood progenitor transplantation ( PBSCT ) propose novel approach treat severe autoimmune disease . Allogeneic BMT currently utilized routine treatment SLE significant morbidity ( GVHD ) mortality associate procedure . We recently develop approach BMT use post-transplant cyclophosphamide allow u safely perform allogeneic BMT match , mismatch , unrelated haploidentical donor . Transplant-related mortality , graft-failure risk GVHD low approach . Furthermore , approach allow u greatly expand donor pool since patient share exactly one HLA haplotype biological parent child half sibling , eligible haploidentical donor identify rapidly nearly case . This trial employ fludarabine + cyclophosphamide conditioning along posttransplantation cyclophosphamide patient refractory SLE . The purpose trial improve salvage rate patient refractory SLE reformatting immune system .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Four American College Rheumatology ( ACR ) criterion classification SLE 4 SLICE criterion Involvement one follow organ system : renal , neurologic , hematologic , cardiac , pulmonary , gastrointestinal A lack response corticosteroid moderatetohigh dos , either equivalent degree immunosuppression azathioprine , methotrexate , cyclosporin , tacrolimus , belimumab , rituximab , mycophenolate mofetil , and/or appropriate treatment Patients eligible transplantation accord BMT Policy Manual Age less 18 year 75 year Any risk pregnancy Patients preterminal moribund</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>